Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Pagel

Showing results (121-130 of 245) with videos related to

Pageof 25
Sort By:
Cancer Research|September 28, 2014
In vivo localization of ⁹⁰Y and ¹⁷⁷Lu radioimmunoconjugates using Cerenkov luminescence imaging in a disseminated murine leukemia modelEthan R Balkin, Aimee Kenoyer, Johnnie J Orozco, et al.
Blood Advances|May 13, 2020
Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndromeJe-Hwan Lee, Stefan Faderl, John M Pagel, et al.
ASAIO Journal (American Society for Artificial Internal Organs : 1992)|April 19, 2020
COVID-19 Respiratory Failure: Targeting Inflammation on VV-ECMO SupportMatthew E Hartman, Roland A Hernandez, Krish Patel, et al.
Cancer Research|February 27, 2009
Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211Hirohisa Nakamae, D Scott Wilbur, Donald K Hamlin, et al.
Blood|November 29, 2007
Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapyJohn M Pagel, Nathan Hedin, Lacey Drouet, et al.
Leukemia|June 4, 2014
Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantationR B Walter, B Gyurkocza, B E Storer, et al.
Leukemia|February 5, 2015
Low platelet count reduces subsequent complete remission rate despite marrow with <5% blasts after AML induction therapyX Chen, L F Newell, H Xie, et al.
Bioconjugate Chemistry|July 6, 2010
Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutantsD Scott Wilbur, Steven I Park, Ming-Kuan Chyan, et al.
JMIR Research Protocols|October 8, 2025
Evaluating the Efficacy of a Mobile Phone App in Enhancing Menopause Knowledge and Shared Decision-Making: Protocol for a Randomized Controlled TrialJana Karam, Maggie M Paul, Chrisandra Shufelt, et al.
American Journal of Hematology|February 18, 2015
Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndromeMazyar Shadman, Raya Mawad, Carol Dean, et al.
Pageof 25

Showing results (121-130 of 245) with videos related to

Sort By:
Pageof 25
Cancer Research|September 28, 2014
In vivo localization of ⁹⁰Y and ¹⁷⁷Lu radioimmunoconjugates using Cerenkov luminescence imaging in a disseminated murine leukemia modelEthan R Balkin, Aimee Kenoyer, Johnnie J Orozco, et al.
Blood Advances|May 13, 2020
Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndromeJe-Hwan Lee, Stefan Faderl, John M Pagel, et al.
ASAIO Journal (American Society for Artificial Internal Organs : 1992)|April 19, 2020
COVID-19 Respiratory Failure: Targeting Inflammation on VV-ECMO SupportMatthew E Hartman, Roland A Hernandez, Krish Patel, et al.
Cancer Research|February 27, 2009
Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211Hirohisa Nakamae, D Scott Wilbur, Donald K Hamlin, et al.
Blood|November 29, 2007
Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapyJohn M Pagel, Nathan Hedin, Lacey Drouet, et al.
Leukemia|June 4, 2014
Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantationR B Walter, B Gyurkocza, B E Storer, et al.
Leukemia|February 5, 2015
Low platelet count reduces subsequent complete remission rate despite marrow with <5% blasts after AML induction therapyX Chen, L F Newell, H Xie, et al.
Bioconjugate Chemistry|July 6, 2010
Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutantsD Scott Wilbur, Steven I Park, Ming-Kuan Chyan, et al.
JMIR Research Protocols|October 8, 2025
Evaluating the Efficacy of a Mobile Phone App in Enhancing Menopause Knowledge and Shared Decision-Making: Protocol for a Randomized Controlled TrialJana Karam, Maggie M Paul, Chrisandra Shufelt, et al.
American Journal of Hematology|February 18, 2015
Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndromeMazyar Shadman, Raya Mawad, Carol Dean, et al.
Pageof 25